Sanofi Pasteur MSD, 8 Rue Jonas Salk, 69367 Lyon Cedex 07, France.
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28.
This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between €9513 and 12,304 per quality-adjusted life year gained, corresponding to €2240-2651 per HZ case avoided and €3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.
这项研究使用已发表的马尔可夫模型评估了法国针对带状疱疹（HZ）和带状疱疹后神经痛的疫苗接种的成本效益。从第三方支付者的角度评估了对 65 岁及以上或 70 至 79 岁人群进行终身疫苗接种的成本效益。结合了法国特定数据以及临床研究的结果，并使用了来自文献的基于国际生活质量的（EuroQol 五维问卷）效用值。在这两个年龄段人群中，HZ 疫苗接种都具有很高的成本效益。增量成本效益比估计在每获得 1 个质量调整生命年（QALY）的 9513 欧元至 12304 欧元之间，相当于每预防 1 例 HZ 病例的成本为 2240 欧元至 2651 欧元，每预防 1 例带状疱疹后神经痛病例的成本为 3539 欧元至 4395 欧元。除了流行病学和临床证据外，经济证据也支持在法国实施 HZ 疫苗接种。
